TrialESMO open2023

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.

H Borghaei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.